Tag: preclinical
-
Organ-on-Chip Model Simulates Blood-Brain Barrier
Researchers at Harvard University developed a chip model of the blood-brain barrier that protects the brain’s nerve cells and tested the model with the drug methamphetamine.
-
Peptide Pain Drugs in Development Aimed at Alternative Targets
Pain drugs made from peptides, small protein-like compounds, and guided by antibodies are being developed as alternatives to prescription opioids to treat moderate to severe pain.
-
Cancer Drug Delivery Through Milk Particles Under Study
A new research project is investigating components in raw cow’s milk that could make it possible to give chemotherapy for cancer as oral drugs rather than infusions.
-
Precision Medicine Technique Devised for Brain Tumors
A process for quickly determining genetic mutations behind brain tumors and delivering a treatment addressing those mutations is shown to extend the survival of lab mice induced with those tumors.
-
Engineered Bacteria Studied for Rare Inherited Skin Disorder
A biotechnology company and research lab are evaluating a modified skin bacteria as a treatment for Netherton syndrome, a rare inherited skin disease affecting mainly infants and young children.
-
NIH Small Business Grant Funds Severe Hepatitis Treatment
A biotechnology company is developing treatments for a severe form of hepatitis, which up to now has only limited therapy options, with a synthetic form of RNA designed to shut down the infecting virus.
-
Drug Discovery System Designed to Identify Difficult Targets
A lab in the U.K. developed a system for discovering new therapies that identify therapy targets linked to enzymes, some found in neurodegenerative diseases, previously considered too difficult to address.
-
Experimental Drug Extends Survival, Reverses Inherited ALS Damage
An experimental drug designed to silence a protein associated with inherited forms of amyotrophic lateral sclerosis, or ALS, is shown in tests with lab rodents to extend survival and reverse some neuromuscular damage.
-
Merck, Biopharma Partner on Cell-Free Immune System Therapies
Drug maker Merck is acquiring the rights to therapies for cancer and autoimmune disorders based on a technology for developing synthetic proteins from a process that bypasses live cells.
-
RNA Nanoparticles Designed for Brain Cancer Therapy
Medical researchers and material scientists devised a technique for delivering tiny particles of genetic material to the brain, which help lab mice shrink or remove their brain tumors and survive longer.